PDT Partners LLC Buys 32,508 Shares of DexCom, Inc. (NASDAQ:DXCM)

PDT Partners LLC increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 164.3% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 52,290 shares of the medical device company’s stock after buying an additional 32,508 shares during the quarter. PDT Partners LLC’s holdings in DexCom were worth $3,506,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Migdal Insurance & Financial Holdings Ltd. bought a new stake in DexCom in the second quarter worth $25,000. Sachetta LLC boosted its stake in DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after purchasing an additional 171 shares in the last quarter. Riverview Trust Co grew its position in DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 232 shares during the last quarter. DT Investment Partners LLC increased its stake in DexCom by 492.2% during the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after purchasing an additional 315 shares in the last quarter. Finally, RPg Family Wealth Advisory LLC bought a new stake in DexCom during the 3rd quarter valued at about $57,000. Institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Sanford C. Bernstein increased their price target on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Raymond James reduced their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a report on Friday, October 25th. Leerink Partners decreased their price target on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Wells Fargo & Company increased their price objective on DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a research report on Friday, October 25th. Finally, Stifel Nicolaus boosted their target price on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, August 23rd. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $104.59.

Insider Activity at DexCom

In related news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This represents a 0.28 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,431 shares of company stock worth $399,319. Corporate insiders own 0.30% of the company’s stock.

DexCom Trading Down 0.1 %

Shares of DexCom stock opened at $77.99 on Friday. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company’s fifty day simple moving average is $71.39 and its 200-day simple moving average is $88.11. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The stock has a market capitalization of $30.46 billion, a PE ratio of 46.70, a P/E/G ratio of 2.39 and a beta of 1.17.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.